PAREXEL enhances early phase clinical development offering for central nervous system studies.
Boston, MA-, June 17, 2008-PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it is expanding its clinical pharmacology capabilities in the Central Nervous System (CNS) therapeutic area. PAREXEL is enhancing existing services in early phase clinical development by adding pain modeling capabilities and combining traditional pharmacodynamic methods with relevant biomarkers, which are surrogate endpoints used to determine safety and efficacy signals.
"CNS diseases, which are reported to account for one third of the world's disease burden, include neurodegenerative diseases such as Alzheimer's and conditions characterized by chronic pain," said Michelle Middle, corporate vice president and worldwide head, clinical pharmacology, PAREXEL. "Our global team of clinical pharmacology experts with in-depth CNS expertise applies various methodologies and biomarkers to help clients make earlier and more effective decisions regarding CNS treatments, and advance this important and growing area of research."
PAREXEL's dedicated clinical pharmacology services directed at alleviation of pain and related symptoms use neuroscience biomarkers to enhance exploration of safety and efficacy and pharmacokinetic analysis. This expanded approach for a broad range of psychiatry, neuropsychopharmacology, neuroimaging, and neurophysiology clinical studies provides greater information about CNS treatments in early phase development. This expertise is aided by the ability to conduct studies with healthy volunteer and patient populations in a time-efficient manner.
PAREXEL, which is a top provider of expertise-based early phase development services from first-in-man to proof of concept, utilizes strategic locations, state-of-the-art technology, and highly qualified and experienced personnel to optimize time and cost savings for clients. PAREXEL's clinical pharmacology business has more than 550 beds, among the largest capacities worldwide. The company's Clinical Pharmacology Research Units are located in Baltimore, MD, and in Los Angeles and San Diego, CA in the United States; London, UK; Berlin, Germany; and Bloemfontein and George, South Africa. PAREXEL also provides early clinical development programs through a joint venture arrangement with Synchron Research based in India.
For more information about PAREXEL's international clinical pharmacology capabilities, visit: http://www.parexel.com/early_phase.html.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.